Drug Trial Radar · NCT06979531
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Jul 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
Conditions
- Primary Sjögren's Syndrome
Interventions
IMVT-1402Drug
Administered once weekly by subcutaneous injection
PlaceboDrug
Administered once weekly by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in clinESSDAI Score at Week 24 for IMVT-1402 Dose 1 compared to PlaceboTime frame: Baseline and at Week 24
Locations
96 sites in 13 countries. Site status is shown where the registry gives one.
Site Number - 1027
Covina, California
Site Number - 1007
El Cajon, California
Site Number - 1016
Menifee, California
Site Number - 1029
Thousand Oaks, California
Site Number - 1026
Upland, California
Site Number - 1014
Fort Collins, Colorado
Site Number - 1018
Hollywood, Florida
Site Number - 1021
Jupiter, Florida
Site Number - 1002
Miami, Florida
Site Number - 1004
Tamarac, Florida
Site Number - 1025
Tampa, Florida
Site Number - 1012
Chicago, Illinois
Site Number - 1033
Orland Park, Illinois
Site Number - 1030
Lake Charles, Louisiana
Site Number - 1028
New Orleans, Louisiana
Site Number - 1032
Canton, New York
Site Number - 1006
Mineola, New York
Site Number - 1013
Philadelphia, Pennsylvania
Site Number - 1015
Jackson, Tennessee
Site Number - 1000
Memphis, Tennessee
Site Number - 1001
Allen, Texas
Site Number - 1020
Amarillo, Texas
Site Number - 1022
Arlington, Texas
Site Number - 1019
Austin, Texas
Site Number - 1024
Grapevine, Texas
Site Number - 1011
Houston, Texas
Site Number - 1010
Houston, Texas
Site Number - 1023
Katy, Texas
Site Number - 1031
San Antonio, Texas
Site Number - 5000
Buenos Aires, Argentina
Site Number - 5002
Buenos Aires, Argentina
Site Number - 5003
Buenos Aires, Argentina
Site Number - 5001
Buenos Aires, Argentina
Site number - 5006
Buenos Aires, Argentina
Site number - 5005
Azcuénaga, Buenos Aires, Argentina
Site Number - 5007
Capital Federal, Buenos Aires, Argentina
Site Number - 5004
San Miguel de Tucumán, Tucumán Province, Argentina
Site Number - 2001
Sherbrooke, Quebec, Canada
Site Number - 2000
Trois-Rivières, Quebec, Canada
Site Number - 5705
Osorno, Chile
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.